Exhibit 99

   CardioDynamics Announces Publication of ICG Hypertension Study;
    57% Blood Pressure Control in Previously Uncontrolled Patients

    SAN DIEGO--(BUSINESS WIRE)--Feb. 12, 2004--CardioDynamics
(Nasdaq:CDIC), the innovator and leader of Impedance Cardiography
(ICG) technology, announced today the publication of an ICG
hypertension study in the February 2004 issue of Congestive Heart
Failure showing a 57 percent blood pressure control rate in previously
uncontrolled hypertensive patients in a generalist physician setting.
Researchers at Harrison Memorial Hospital, Bremerton, Wash., treated
resistant hypertensive patients on two anti-hypertensive medications
using the BioZ and Mayo Clinic hypertension algorithm. Over a
three-month period, 57 percent of these previously uncontrolled
patients achieved blood pressure under 140/90 with the aid of
ICG-guided therapy.
    The study's investigators concluded, "Our results demonstrate
superior blood pressure control using a treatment algorithm and serial
hemodynamic measurements compared with clinical judgment alone in a
randomized prospective study. In subjects with uncontrolled blood
pressure on two antihypertensive agents, ICG-guided pharmacologic
decision-making resulted in a significant reduction in blood pressure
and improvement in blood pressure control. ICG is a safe, effective,
and cost-effective tool to assist community generalists treating
uncontrolled hypertension."
    Previously, researchers at the Mayo Clinic developed an ICG
algorithm as part of their study published in the May 17, 2002 issue
of Hypertension, demonstrating a 70 percent improvement in blood
pressure control with ICG-guided therapy. The Mayo study involved
physicians who specialized in treating drug-resistant high blood
pressure patients. Drug-resistant hypertensive patients are a
challenge to any physician, especially internists and generalists
(family practice) because treatment is highly subjective and there are
a large number of available pharmacologic options. The customized ICG
algorithm is a beneficial tool to assist physicians in noninvasively
and accurately determining patients' hemodynamics (blood flow,
vascular resistance and fluid levels), guiding drug selection and
measuring patient responses to the pharmacologic treatment. This new,
individualized approach to treatment provides an objective roadmap in
the treatment of patients affected by resistant hypertension who
previously have been treated on a subjective basis.
    "Clinical studies and publications in peer-reviewed journals are
the primary means for clinicians to become aware of the availability
and significance of our technology," stated Michael K. Perry,
CardioDynamics' chief executive officer. "While a significant amount
of evidence substantiating ICG's clinical application is available,
publications such as Congestive Heart Failure provide valuable
exposure to our technology. High blood pressure is a risk factor for
heart disease, and ICG has proven to play an important role in helping
physicians determine the underlying cause and to target treatment."

    About CardioDynamics

    CardioDynamics, the ICG Company, is the innovator and leader of
breakthrough medical technology called Impedance Cardiography (ICG).
The company's BioZ Systems are being used by leading physicians around
the world to help battle the number one killer of men and women --
cardiovascular disease. Partners include GE Medical Systems
Information Technologies and Philips Medical Systems. The worldwide
market potential for BioZ products is estimated to be $5 billion and
an additional $800 million in recurring annual revenue for sensors.
For additional information or to request an investor package, refer to
the company's Web site at www.cdic.com.

    Forward-Looking (Safe Harbor) Statement

    Except for the historical and factual information contained
herein, this press release contains forward-looking statements, such
as market size, potential, growth and penetration rates, the accuracy
of which is necessarily subject to uncertainties and risks including
the company's sole dependence on the BioZ product line, and various
uncertainties characteristic of early growth companies, as well as
other risks detailed in the company's filings with the SEC, including
its 2002 Form 10-K. The company does not undertake to update the
disclosures contained in this press release.

    CONTACT: CardioDynamics, San Diego
             Investor Relations:
             Bonnie Ortega, 800-778-4825, ext. 1005
             bonnie@cdic.com
                or
             Media Relations:
             Irene Paigah, 800-778-4825, ext. 1012
             ip@cdic.com